SCROLL NEWS / DISCOVERY
Search headlines
Find the stories shaping the conversation.
Results for " Cardiovascular " 517 found 🔀 AI-powered Shuffle
FDA clears AI software for limiting false-positive ICM alerts
The cloud-based software from Implicity was built to help care teams reduce unnecessary alerts and prioritize patients who truly need care.
Abbott gathering real-world data on FDA-approved TriClip system
Abbott's TriClip system for tricuspid regurgitation is approved by the FDA and covered by Medicare. To learn more about its real-world performance, researchers will now track 1,000 patients for a total of five years.
Overlooked plant proteins may boost gut health
Plant-based diets are good for you. They promote gut, immune, metabolic and cardiovascular health, in part by cultivating a diverse community of intestinal bacteria. These benefits have long been known ...
New STS guideline tackles the prevention of AFib after cardiac surgery
Among the guideline's most significant changes is a Class I recommendation for prophylactic amiodarone.
Cardiologist arrested for allegedly sexually abusing patients—officials seek other victims
The cardiologist, 63, was arrested on charges of rape, sexual battery and gross sexual imposition. The Brown County Sheriff's Office believes there are additional victims who have not yet come forward.
Antibiotic recalled after cardboard particles found in solution
Patients given the drug in question could face an increased risk of blood vessel blockages or inflammation.
Swallowed needle leads to serious heart damage—persistent care saves the day
The patient, it turned out, had a habit of holding sewing needles in his mouth while he worked as a tailor. He did not mention this at first, however, creating quite a challenge for his care team.
FDA shares warning about stroke prevention device after injury
Customers should return these devices to the manufacturer, Boston Scientific, due to a risk of the tip separatng during use.
Prescriptions for nutrition: Nevada program connects food banks to health care
For families across northern Nevada, fresh groceries can mean the difference between costly health outcomes and fewer trips to the emergency room. Poor nutrition remains one of the leading risk factors for cardiovascular disease and other health disparities in the U.S., according to health experts. Early research also indicates that “food as medicine” initiatives including […]
Planetary Health Diet lowers cardiovascular risk in older women
A 20-year study of more than 65,000 postmenopausal women found that higher adherence to the Planetary Health Diet was associated with a lower risk of overall cardiovascular disease, coronary heart disease, stroke and heart failure.
ACC shares updated recommendations for managing HFpEF
A team of specialists detailed new data and recent breakthroughs in the diagnosis, management and treatment of heart failure with preserved ejection fraction.
CCTA being used more and more to plan ahead before complex PCI
Interventional cardiologist Yader Sandoval, MD, discusses the growing trend of using CCTA imaging to plan ahead before complex PCI procedures.
SCCT highlights payment gains, policy challenges as coronary CT use surges
An increase of nearly 200% in the use of CCTA over the past year has driven policy changes.
Coronary CT imaging is reshaping cardiovascular prevention
Cardiac imaging expert Ron Blankstein, MD, Brigham and Women's Hospital, provides an overview of how CCTA may soon become a paradigm shift in cardiac prevention.
Surgeon hails new CABG technology as a 'technical breakthrough'
The new-look ELANA device from AMT Medical could simplify CABG procedures and help improve patient access to minimally invasive and robotic surgical techniques.
Failure to rescue after TAVR: New study tracks outcomes at high- and low-volume hospitals
High-volume hospitals are often associated with better TAVR outcomes. The team behind this new study wanted to see if a similar trend was seen with FTR rates as well.
Cardiologist named chief medical officer of wearable tech company Whoop
Ami B. Bhatt, MD, a veteran cardiologist and digital health specialist, stepped down as the American College of Cardiology's chief innovation officer to accept this new role.
FDA sees early promise in new gene therapy for BAG3-associated DCM
An investigational drug therapy from Affinia Therapeutics has secured the FDA's orphan drug designation. This means the company now has access to certain benefits, including tax credits and fee exemptions, as it works toward approval.
Well-known cardiologist named chief medical officer of wearable tech company Whoop
Ami B. Bhatt, MD, a veteran cardiologist and digital health specialist, stepped down as the American College of Cardiology's chief innovation officer to accept this new role.
Prolonged exposure to wildfire smoke increases cardiovascular health risks
Repeated and cumulative exposure to wildfire smoke is linked to a higher risk of being hospitalized for cardiovascular disease in older adults in the U.S., a new Yale study finds.
Less invasive anesthesia strategies during TAVR linked to a key benefit
Long-term TAVR outcomes were comparable. When tracking 30-day data, however, researchers found that hospital readmission was much less common for patients treated with regional anesthesia or moderate sedation.
Novo Nordisk sues GLP-1 rival Eli Lilly over claims of false advertising
Novo Nordisk filed a lawsuit claiming Eli Lilly ran “false and materially misleading” advertisements that ignore recent data. According to Lilly, though, its message is "truthful" and "grounded in the most direct scientific evidence available."
Behind the Science: Can IL-6 Improve Cardiovascular Risk Assessment? Findings From the CCC Study
Discover the socio-demographic impacts on cardiovascular mortality in our JACC webinar. Join experts as they share insights and strategies for better heart health.
Penn State Health hospitals nationally recognized for commitment to excellence in cardiovascular and stroke care
Penn State Health’s hospitals have been recognized by the American Heart Association for excellence in heart disease and stroke treatment. The awards honor sustained adherence to research-based…
Penn State Health nationally recognized for cardiovascular, stroke care
Penn State Health’s hospitals have been recognized by the American Heart Association for excellence in heart disease and stroke treatment. The awards honor sustained adherence to research-based guidelines that improve patient care and outcomes.
How much coffee is safe for the heart? Doctors explore the benefits and risks of caffeine
Drinking multiple cups of coffee each day may decrease a person's risk of heart disease, heart failure and stroke. Too much caffeine can still cause issues, however, when taken as energy drinks.
Heartflow launches new AI-powered staging tool for coronary plaque assessments
In addition to launching Heartflow Plaque Staging, the company also shared new data at SCCT2026 highlighting the importance of using total plaque volume assessments to diagnose and manage heart patients.
New AI blood test predicts heart disease 15 years early
A new AI-powered blood test could give people a remarkably early warning of serious heart and circulation problems. Developed by researchers at the University of Hong Kong, CardiOmicScore analyzes thousands of proteins and metabolites to estimate the risk of six major cardiovascular diseases, including heart attack, stroke, heart failure, and atrial fibrillation. Unlike genetic risk scores, which remain fixed throughout life, the system captures biological changes linked to a person’s current health, lifestyle, and environment.
Medical societies take a stand as CMS nears final decision on TAVR proposal
Back in June, CMS proposed significant updates to its current TAVR policies. Three leading healthcare societies have now joined forces to share their own perspective on the potential updates.
Recall update: FDA now urging clinicians to return vascular device linked to 3 deaths
Cardiologists and vascular surgeons were previously told they could still use the device if necessary. Now, however, the message is that they should return the product to the manufacturer.
Wegovy, weight loss and cardiovascular health: A closer look at how semaglutide protects the heart
When patients take semaglutide, the dose appears to offer more cardiovascular benefits than weight loss.
How AI can help heart teams identify TAVR patients
Many heart patients who would benefit from TAVR are still missing out on the care they need. AI, it turns out, can help cardiologists find those patients. An upcoming webinar is set to explore this topic at length.
Medtronic recalls surgical devices due to risk of blood contamination
Trace amounts of blood were identified within the sealed packaging of these devices. No patients were exposed to the foreign material, and no adverse events were reported, but Medtronic is recalling the devices as a precaution.
Stereotaxis completes major cardiology tech acquisition
The deal, first announced in April, includes an upfront payment of $20 million and up to an additional $25 million based on certain milestones.
FDA approves first cholesterol pill of its kind
Enlicitide, the new oral PCSK9 inhibitor from Merck, will be sold under the brand name Lipfendra. It is approved to reduce LDL-C in patients with hypercholesterolemia, including HeFH.
The crisis continues: Nearly 90% of deaths from ischemic heart disease could have been prevented
There has been progress over the years, researchers noted, but there is still a lot of work to do.
CMS proposes Medicare payment cuts in 2027—physician groups pledge to bring about change
Cardiologists received a nice bump in pay in 2026 thanks to a one-time 2.5% conversion factor increase. That expires at the end of the year, however, and physicians will see their payments decrease as a result.
Heart surgeon makes history, performs first robotic procedure of its kind
A surgeon in Michigan has performed the world’s first single-port robotic mitral valve repair.
Chico State seeks night shift participants for cardiovascular and muscle health study
Chico State University is recruiting participants for a research study examining the effects of night shift work on cardiovascular and muscle health.
Semaglutide dose may matter more than weight loss for heart health
The study shows semaglutide's cardiovascular benefits are more closely tied to attained dose than weight loss, challenging existing treatment assumptions.
Cardiologist’s lawsuit against former employer dismissed
The lawsuit Hemal Gada, MD, filed against UPMC has been dismissed with prejudice.
Acute kidney injury after TAVR: Simple biomarker helps cardiologists identify high-risk patients
The CALLY index, a biomarker that examines systemic inflammation, immune system activity and nutrition, could provide care teams with significant value.
New SCCT president, a veteran cardiologist, highlights importance of listening and teamwork
New SCCT president Ronen Rubinshtein, MD, says the fields of interventional cardiology and cardiac imaging are two of his greatest interests.
Your resting heart rate could reveal more about your health than you think, doctors say
Here is what your resting heart rate reveals about cardiovascular health and when to see your doctor. Pulse checks and wearable devices can help with measuring the rate.
GLP-1 drugs linked to long-term benefits for PAD patients
PAD patients treated with GLP-1 receptor agonists lived longer, stayed out of the hospital more and experienced fewer amputations than those given metformin.
Topaz vs. Evoque: New head-to-head study for TTVR devices now underway
Researchers are comparing the new-look Topaz TTVR system from TRiCares with the FDA-approved Evoque TTVR system from Edwards Lifesciences.
Why DAPT with aspirin after PCI is still a good idea
Immediate aspirin discontinuation after PCI is associated with an increased risk of ischemic events, according to a new analysis of nearly 8,000 patients.
Joint Society Editorial Calls For Science-Based Approach to CV Health Equity
A joint editorial on behalf of the ACC, American Heart Association, European Society of Cardiology and World Heart Federation calls for a new era of equity-centered cardiovascular care designed to redefine prevention, optimize care delivery and ensure that all patients worldwide benefit equally from the promise of modern cardiovascular medicine.
WHO calls for urgent action as new cancer cases are projected to nearly double by 2050
Millions of people are facing physical, emotional and financial toll of cancer, a disease that claims more than 26 000 lives every day, according to a report released today by the World Health Organization (WHO). With an estimated 20.6 million new cases and close to 10 million deaths annually, cancer remains the second leading cause of death globally, after cardiovascular disease.
Why cardiology leaders should be careful about the quality metrics they focus on
"Data should simply be a measure of a broader organizational objective," one expert explained. "When the data becomes the goal, that's where organizations can get into trouble."
Exploring key breakthroughs in VT ablation
Today's sophisticated mapping systems allow clinicians to visualize VT circuits with unprecedented detail.
ACC takes on DOAC use with new scientific statement
Direct oral anticoagulants continue to be underutilized and inappropriately dosed. The American College of Cardiology hopes a new scientific statement can help address those issues and provide clinicians with an updated look at this important topic.
Medtronic recalls heart valve delivery system due to safety risk
The same device was previously recalled back in 2022. Customers are urged to return unused delivery systems to Medtronic to avoid any issues.
Why Circulation Health Supplements Are Gaining Attention for Supporting Healthy Vascular Function and Everyday Wellness, According to PureHealth Research
PureHealth Research is highlighting growing consumer interest in circulation wellness and the role of targeted nutritional supplementation in maintaining healthy blood flow, vascular function, and overall cardiovascular wellness.Circulation health supplements commonly feature ingredients such as Omega-3 Fatty Acids, Berberine and Butcher's Broom, which are frequently included in formulations designed to promote healthy circulation and vascular health.
Health forum gives East Texans steps to prevent heart disease death
Nearly 700,000 people in the U.S. died of heart disease in 2023, but experts say many cardiovascular problems are preventable.
FDA clears AI-enabled CCTA plaque analysis tool from Keya Medical
The company now has multiple FDA-cleared algorithms for evaluating CCTA results.
American College of Cardiology celebrates 100 hospitals for offering ‘highest level of cardiovascular care’
These "forward-thinking organizations" have all committed to participating in multiple data registries and quality improvement programs. Did your facility make the cut?
Cardiologist Manesh Patel named new American Heart Association president
Patel, a veteran interventional cardiologist with Duke Health, was named the group's Physician of the Year in 2023.
New York cardiologist performs first procedure in US with FDA-cleared imaging tech
The OpusWave Dual Sensor Imaging captures both IVUS and OFDI, providing users with two complementary views of the coronaries at the same time.
Parents charged with murder after 7-year-old son died of heart disease at 255 pounds
The young boy was allegedly living on a diet of potato chips, French fries and other unhealthy snacks. One prosecutor described the case as "extraordinary, terrible neglect."
FDA approves surgical device for high-risk aortic procedures
The AMDS Hybrid Prosthesis was designed to help clinicians treat DeBakey Type 1 dissections complicated by malperfusion. It works as a complement to hemiarch replacement, preserving the native arch and making reinterventions possible if needed.
Efzimfotase alfa demonstrated improvements in bone health in treatment-naïve pediatric patients with hypophosphatasia achieving median difference of 1.67 vs placebo in RGI-C Score at week 25 in MULBERRY Phase III trial
Positive results from the MULBERRY Phase III trial showed that efzimfotase alfa (ALXN1850), an investigational enzyme replacement therapy, demonstrated a statistically significant and clinically meaningful improvement in bone health in children (2 to
Just 2 Hours of Strength Training May Lower Heart Disease Risk in Women
Researchers say that just 2 hours of weekly strength training may help lower the risk of cardiovascular disease in women, especially when paired with 150 minutes of weekly aerobic exercise.
Americans keep poisoning themselves with semaglutide, other weight loss drugs
These incidents became much more common after the FDA started approving GLP-1 drugs for chronic weight management in 2021.
Why where you live matters for heart health — even in childhood - Baylor College of Medicine Blog Network
Evidence links environmental exposures to early cardiovascular risk, disproportionately impacting marginalized communities like AI/AN youth.
Shockwave Medical announces new studies evaluating carotid IVL platform
Carotid artery disease causes up to 30% of all strokes, but severely calcified lesions can make treatment quite complex. The hope is that IVL can be as successful in this area as it has been in the treatment of coronary and peripheral artery disease.
Making Our Own Luck
We are cross-posting a piece that former NIH official Kris Willis wrote for Macroscience. Kris is now the President and Founder of the Woodley Park Institute, for which I’m a board member. Picking winners or hedging bets? Federal science agencies have long wrestled with the question of how to ensure their billions of dollars of grants and contracts result in maximum benefits for Americans. On the surface, it might seem that a goal-oriented, interventionist style of management would be the best policy: prioritize our most pressing problems and distribute funding accordingly.This top-down strategy creates a unique hazard, though: bad choices can send resources in the wrong direction, resulting in slow progress that impedes the delivery of tangible benefits to citizens. Moreover, if decision makers pursue an applied advance when the underlying scientific principles remain poorly understood, they risk costly failures and a loss of support for the research enterprise at large. Examples include Nixon’s 1971 War on Cancer, undertaken on the premise that a cure could be achieved in less than a decade, the drive to build an operational commercial fusion plant by the mid-1990s, and the National Plan to Address Alzheimer’s Disease, which failed to produce the effective treatments and prevention strategies promised by 2025. The contrasting laissez-faire approach is to hedge your bets. If the path to an advance is impossible to predict, then the wisest choice might be to distribute funding to as widely as possible. The main risk of this strategy is that spreading funding thinly may limit the resources available to the most promising research, resulting in the same negative outcomes as the interventionist approach: limited support for the most promising topics, slow progress, and delayed returns. In reality, at science agencies like the National Science Foundation and National Institutes of Health, program managers navigate between these two extremes, setting some funds aside to target high-priority areas and using the rest to cover the widest possible range of meritorious proposals. This middle path seems like the most rational way to proceed, but it still requires making choices. How much should be set aside for high priority topics? What should those topics be? How should we define merit? Expert opinion can provide a helpful guide, but leading experts can have remarkably different opinions about what matters and what should be prioritized. Moreover, experts and administrators alike can be risk averse, giving an edge to high-profile, well-established concepts. What’s really needed is a data-driven framework to help guide decision-making, one that doesn’t simply repackage prestige or incumbency. Recognizing breakthroughs years in advance Many breakthroughs fail to attract funding or recognition at the earliest stages of development. Katalin Karikó, for example, spent years struggling to win grants for work on mRNA that would eventually win her and Drew Weissman a Nobel Prize. Similar stories can be told about Jim Allison’s groundbreaking studies leading to the development of cancer immunotherapy, Stan Pruisner’s demonstration that prions can self-replicate without DNA, or Robin Warren and Barry Marshall’s proof that Helicobacter pylori, not stress, causes ulcers. Yet at some point, the scientific community recognizes and responds to transformative breakthroughs like these. How does that change happen? And what if science funders could identify the areas that are on the cusp of a breakthrough? Those questions led my collaborators and me to study how scientists responded to past breakthroughs. Based on patterns in that data, we developed a means of predicting future breakthroughs, using biomedicine as a proof of concept. It’s worth taking a moment to describe how our approach works. Briefly, our prediction process begins by grouping the 18 million or so peer-reviewed papers in PubMed, the authoritative database of biomedical research, into roughly 50,000 unique topics. A small subset of these topics are so widely acclaimed as breakthroughs that they have been recognized with a major prize like a Nobel or a Lasker Award. We theorized that studying the development of these outliers over time, especially before they gained acclaim, was the key to identifying future instances of them. After defining topics, we chose 21 representative breakthroughs and asked what they looked like before they won prestigious prizes. To answer that question, we re-ran our topic-mapping algorithm repeatedly, winding back the clock one year each time, stringing together the years to follow the progress of each field as it grew and advanced. We found that in each case, the years leading up to a discovery followed a pattern: a burst of papers on a new, rapidly evolving topic, many of which quickly became influential. These characteristics—the percent of papers that are new, the percentage of papers that are brought in from other topics, and the influence of each individual paper—can all be measured separately for any given topic. Together, they act as a predictive signal that is detectable an average of five years before a transformative discovery is made, and up to thirty years before the discovery receives a major prize. Scanning the current research landscape for topics that display this signal allows us to predict what work will likely produce a future breakthrough. Each year we analyzed includes four or five signals, a number that appears to have remained constant across a twenty year time frame. In their classic work on the sociology of science, Bruno Latour and Steve Woolgar established that the desire to participate in a major discovery is an important motivator for scientists as they consider whether they should take up (or abandon) a research problem. Although further work is needed, the simplest explanation for our results is that this behavior is widespread enough to detect at scale. A foundational advance, or something like it, draws the attention of scientists and causes them to change the direction of their research. They vote with their feet, staking their own reputation and careers by publishing on and citing the new idea. That upswell of interest is the foundation of our breakthrough signal. What kind of research does our model identify as a breakthrough? After building a model based on the patterns in our 21 preselected breakthroughs, we tested it by identifying all early signals of discovery from 1994 through 1997. Of the 18 signals we found in that time period, 17 can be traced forward in time to a breakthrough. Examples include super-resolution fluorescence microscopy (see the image above), the directed evolution of proteins and enzymes (Chemistry Nobel, 2018), and sequencing the human genome (National Medal of Science, 2008). The discovery of the role of leptin signaling in obesity is a particularly interesting case study. Around 1950, scientists noticed the existence of a type of lab mouse that suffered from a unique inherited form of obesity. When given the freedom to choose their own diet, these mice ate more than normal and preferred food that was high in fat. Researchers had few clues as to why the animals overate; early experiments pointed to the existence of a soluble ob factor found circulating in the bloodstream that regulated appetite, but its identity was unknown. In 1994, Jeffrey Friedman and colleagues identified and sequenced the ob gene, noting that the protein it encoded appeared to fit the profile of a circulating factor. A year later, a trio of high-profile publications demonstrated that ob was a hormone that regulated body weight and fat deposition by regulating appetite. One of these was co-authored by Friedman, who christened it leptin from the ancient Greek word for thin. Using our model, the data from 1996 make it clear this advance would become a breakthrough. Scientists had flocked to study the biology of the new hormone, generating the flurry of new papers and citations required to produce a signal. One of these demonstrated that serum leptin concentrations reflected the amount of adipose tissue in the human body, providing clinical validation of the earlier mouse studies. Before the identification of leptin, scientists were unable to point to a specific molecule that controlled appetite and adiposity, so that it was impossible to rule out non-physiological causes of obesity; its characterization fundamentally changed our concept of weight gain. In 2010, Friedman and fellow pioneer Douglas Coleman were awarded a Lasker for the discovery. Our work also identifies breakthroughs in clinical practice and behavioral and social sciences, even though these areas are less likely to draw the attention of major prize committees. One example that falls into this category is the introduction of endovascular aneurysm repair, a minimally invasive surgical procedure for the treatment of abdominal aortic aneurysm, a leading cause of death among Americans over the age of 65. Relative to the previous standard of care, it reduces in-hospital mortality by almost four-fold. In 2017, Timothy Chuter received the American College of Surgeons’ prestigious Jacobsen Innovation award for his multiple refinements to the technique. Another under-recognized breakthrough identified by our model is the development of standardized survey instruments to assess the quality of life for HIV+ patients. The antiretroviral cocktails introduced in the mid-1990s reduced AIDS mortality, but treatment came with serious side effects. The new evaluations showed that patients whose disease progressed had worse physical functioning than Americans with other chronic diseases, while those who were asymptomatic maintained a health-related quality of life on par with the overall US population. This evidence made it possible for patients and activists to argue that even in the absence of a total cure, and in spite of the side effects, alleviation of symptoms was a worthwhile priority for clinicians. My colleagues and I have failed to identify any significant recognition for the physicians and health policy experts who pioneered this advance, although in 2016, researchers called for the World Health Organization to set targets for good health-related quality of life as part of its framework to end the AIDS pandemic. From forecasting to funding How should science funders use our predictions? Any serious discussion of what we should do with this new capability needs to begin with an understanding of its limitations. We can’t (and shouldn’t) invest all of our resources in the small number of topics predicted to produce breakthroughs. Innovative new fields are born from existing ones; they rarely arise de novo. If funders don’t maintain a diverse portfolio, the breakthroughs of tomorrow will have no antecedents. Think of this as eating the seed corn, or killing the goose that lays the golden egg. There are also multiple goals of funding beyond basic scientific discovery, including translating discoveries into clinical practice, developing new technologies, supporting economic development, and training new scientists. The investments needed to accomplish these goals are likely different from those required to support emerging breakthroughs. Finally, we must be aware that we may not capture every instance of a breakthrough. The concept is fuzzy, and not every significant discovery is recognized with a major award. Further, breakthroughs are rare, meaning that our dataset is, by necessity, small. This makes formal estimates of accuracy challenging. Although our overall success rate appears to be high, any one signal may turn out to be a false positive. We found one apparent example: the development of the third generation COX-2 inhibitors, Vioxx and Celebrex, which were much celebrated in the early 2000s as effective but non-addictive pain relievers, meets all the algorithmic criteria of a breakthrough. Five years after it received FDA approval, researchers demonstrated that Vioxx was associated with serious cardiovascular complications, and the manufacturer voluntarily pulled the drug from the market. Celebrex remains available, although like other NSAIDs, it carries an FDA warning for increased cardiovascular risk. Decision makers who were overly focused on the breakthrough potential of this research might have wasted substantial resources nurturing an area that ultimately proved to be a failure—but so would those who relied on expert opinion at the time. That said, the potential benefits of funding the next mRNA vaccine or cancer immunotherapy years earlier than we might have are large. When we can’t assume the outcome of an action, it’s worth conducting an experiment. Can targeted support for areas that are poised to produce a breakthrough increase the return on scientific investment without cannibalizing future advances? With the necessary administrative infrastructure in place, conducting this experiment would be straightforward. First, identify all the breakthrough signals between 2018 and 2023, select half at random, and commit to a decade of investment. For biomedicine, a six year window should yield about 30 topics with the potential to produce a breakthrough. Providing strong support to half of these might be accomplished for $300 million a year. That’s roughly half of the recent annual budget of the NIH Common Fund or around 20% of the fiscal year 2025 budget for ARPA-H. After five years, then again at ten, compare to see which group — the one that was actively managed, or the control — produced more breakthroughs, and on what timescale. Although we used biomedicine as an example, the same experiment could just as well be run for physics, materials science, or any other discipline. Any attempt to undertake such an experiment should keep three points top of mind. First, we can predict the topic of future breakthroughs, but the people and vision for how to move the work forward are still important. In practice, this means success requires active program managers with the expertise to develop the science and the authority to do so, including by recruiting investigators. Second, we would be wise to learn from the failures of past attempts to fund transformative research. High among these are funding modestly repackaged work, confusing the genuinely novel with the merely unfamiliar, and relying too much on incumbent investigators. All of these risks can be mitigated by thoroughly and intelligently integrating high quality data into portfolio management. Finally, we need to have patience. Even with strong funding support, producing a breakthrough takes time. If supporting breakthroughs is the best way to nurture the birth of new fields, we also need to accurately describe and properly manage the other two stages, so that we invest wisely throughout the productive lifetime of ideas and divest once they reach the point of diminishing returns. We would benefit from more study of all of these phases, especially the transition from one to another. More research could answer questions like: When does a breakthrough become an established field? How do the availability of funding, the size and characteristics of the available workforce, and the accumulation of evidence that disagrees with prevailing models affect a field’s decline? Exactly how do old ideas give birth to new ones, and can we speed up the process? The more we understand about the dynamics of scientific progress, the better we can maximize the odds that our curiosity leads to results. I’d call that finding a way to make our own luck.
Latest COVID booster may offer bonus health benefit, study suggests
The latest COVID-19 vaccine (2024-2025) has been linked to fewer serious heart-related events among U.S. veterans. New research confirmed a small reduction in COVID-related cardiovascular events, or COVID-19-associated MACE, due to the vaccine.
20 everyday habits that affect your heart health
Cardiovascular disease is the world's leading cause of death — and most of its risk factors are behavioral, not genetic. These are the daily habits that matter most
FDA clears AI software for flagging signs of vascular disease
The newly cleared software alerts clinicians when it detects a suspected vascular occlusion.
Texas doctor charged in $89M fraud case as administration pushes health care crackdown
The Justice Department has charged a Texas doctor in an $89 million health care fraud scheme, accusing him of billing insurers for medically unnecessary cardiovascular screening tests.
Texas doctor charged in $89M fraud case as administration pushes healthcare crackdown
The Justice Department says it has charged a Texas doctor in an $89 million healthcare fraud scheme, accusing him of billing insurers for medically unnecessary cardiovascular screening tests for college student-athletes and then rubber-stamping the res...
Private equity unlikely to dominate cardiology despite hype
Medaxiom CEO Jerry Blackwell, MD, MBA, FACC, discusses investor's interest in buying cardiology practices, noting that PE ownership remains relatively low.
Cardiology groups strongly oppose expansion of Medicare AI prior authorization model
ASE, ASNC and SCAI have come out against a WiSER model using AI for traditional Medicare prior authorizations.
The Pulse: Women's Health is Having a Reckoning - The Longevity Gap is Where it Starts
Welcome to our new series The Pulse, covering everything you need to know about the age of intelligent health.From ovarian aging and maternal health to cardiovascular and dementia risk, HLTH USA 2026 is programming the women’s health conversations medicine has been too slow to have.While women live longer than men, they spend 25% longer in poor health. The healthspan gap, between how long women live and how long they live in good health, is the defining focus of the next frontier in women’s health. “Diminished healthspan ...
First US patient enrolled in device study to reduce coronary microvascular dysfunction
The self-expanding A-Flux device is implanted in the coronary sinus to increase pressure on the venous side of the heart and improve perfusion in smaller vessels.
Advances in leadless conduction and Bachmann’s bundle pacing next frontier in physiologic pacing
Leadless pacing in the Bachmann's bundle may be the next phase in the evolution of cardiac pacing technology.
Smartphones passively monitor heart health
Nature Reviews Electrical Engineering - A study in Nature uses deep learning to passively monitor resting heart rates via front-facing smartphone cameras, yielding highly accurate cardiovascular...
Do wearables actually help people with cardiovascular disease?
In this edition of STAT Health Tech: A look at what researchers found about if using wearables help people with cardiovascular diseases, and more.
Researchers found 8 common food additives linked to high blood pressure and heart disease
A major study of more than 112,000 people found that eating foods containing common preservatives may be linked to a higher risk of high blood pressure and heart-related diseases. Researchers tracked participants for up to eight years and discovered that people consuming the highest amounts of certain preservatives had significantly greater risks of hypertension, heart attack, stroke, and other cardiovascular problems.
More than 11K bottles of blood pressure drug recalled
Certain lots of a popular diuretic have been recalled due to concerns about the drug's effectiveness.
'Not sustainable': The real impact of RVU cuts in electrophysiology
Despite a substantial increase in demand for electrophysiologists, payments for their services have remained stagnant.
Family files $17M lawsuit after young girl’s heart valve allegedly implanted upside down
Days went by and the girl's doctors allegedly never figured out what was wrong. When she was transferred to a different hospital, however, the issue was quickly identified and corrected.
CMS proposes major TAVR changes, including Medicare coverage for asymptomatic patients
After months of consideration, CMS has proposed sweeping changes to its TAVR coverage policies. The agency is accepting public comments until July 15.
Covid vaccine linked to broad protections against heart conditions, study finds
The vaccine modestly reduced cardiovascular conditions, hospitalizations and deaths of all causes, including those not linked to covid, researchers said.
UC wins $3.3M grant to study microplastics' effects on cardiovascular health
Microplastics are in the food people eat, the water they drink and the air they breathe. UC researchers are studying the impact microplastics have on the heart.
Medline recalls nearly 50K procedure kits, including many used by cardiologists
This recall was put in place due to a risk of the included adhesive not working. Nothing needs to be returned, but clinicians should not use the adhesive that comes inside the procedure kits.
Medtronic completes $550M acquisition of neurovascular company
Scientia Vascular, a medtech company focused on advanced stroke therapies, is now officially part of Medtronic.
Optimize health to combat cardiovascular disease
The threat of heart disease and stroke is growing substantially among women and girls as rates climb for health factors such as high blood pressure, diabetes and obesity, with 6
FDA clears new computer-assisted device for removing clots in stroke patients
The Thunderbolt device from California-based Penumbra uses modulated aspiration to detect and remove blood clots. Back in January, Boston Scientific agreed to acquire Penumbra for approximately $14.5 billion.
Redo TAVR with balloon-expandable valves linked to positive outcomes, key improvements
Researchers tracked real-world data from more than 140 patients who originally received a transcatheter heart valve from Edwards Lifesciences, Medtronic or Boston Scientific.
Study finds 5 daily servings may fall short of key heart-health compounds
Researchers report that many people in the U.S. and U.K. are not consuming levels of flavanol-rich fruits and vegetables associated with better cardiovascular outcomes.
Austin’s young professionals community is red hot for heart health
AUSTIN, June 12, 2026 —Cardiovascular disease and stroke can affect anybody, of any age – and the young professionals community in Austin is turning up the heat to make sure everyone is prepared to save a life. The American Heart Association’s Young...
Scientists found the strength training sweet spot for a longer life
Just 90–120 minutes of strength training a week may deliver some of the biggest long-term health rewards, according to a study tracking more than 147,000 people for 30 years. That amount was linked to lower risks of death overall, particularly from cardiovascular and neurological diseases. Combining strength workouts with aerobic exercise produced even stronger benefits.
Scientists found the strength training sweet spot for a longer life
Just 90–120 minutes of strength training a week may deliver some of the biggest long-term health rewards, according to a study tracking more than 147,000 people for 30 years. That amount was linked to lower risks of death overall, particularly from cardiovascular and neurological diseases. Combining strength workouts with aerobic exercise produced even stronger benefits.
Death after TAVR: New data support use of better patient assessments
A vast majority of patient deaths in the first year after TAVR have nothing to do with heart health. Could care teams be doing more to identify high-risk patients?
Heart Health Biotech Kardigan Seeks $373.3 Million in US IPO
Kardigan Inc. is seeking to raise $373.3 million in a US initial public offering to help fund three late-stage drugs that target cardiovascular diseases.
PAD patients minimize risk when they listen to their doctors
Patients who exercise and take all prescribed medications, for instance, experience better outcomes than those who do not.
ACC-AHA release first cardiovascular-kidney-metabolic syndrome guideline
Science shows the deep relationship between cardiac, kidney and metabolism issues that may impact up to 90% of the U.S. population.
ACC-AHA release first cardiovascular-kidney-metabolic syndrome guideline
Science shows the deep relationship between cardiac, kidney and metabolism issues that may impact up to 90% of the U.S. population.